Additionally, MSC exosomes from AML patients have been reported to protect leukemic cells carrying the fms like tyrosine kinase 3 (FLT3) internal tandem duplication from treatment with the AC220 specific FLT3 inhibitor [65]. Here, FLT3 is linked to acute myeloid leukemia.